{"id":"combined-therapy-sof-and-dcv","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir inhibits the hepatitis C virus RNA-dependent RNA polymerase (NS5B), preventing viral RNA synthesis. Daclatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Together, these agents provide complementary antiviral activity with a high barrier to resistance development.","oneSentence":"This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:18.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent)"}]},"trialDetails":[{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT03540212","phase":"PHASE2, PHASE3","title":"Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-12-10","conditions":"Chronic HCV Infection","enrollment":50},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03080415","phase":"PHASE3","title":"Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir","status":"COMPLETED","sponsor":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","startDate":"2017-03-18","conditions":"Hepatitis C Genotype 4","enrollment":40},{"nctId":"NCT02576314","phase":"PHASE3","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05","conditions":"Chronic Hepatitis C Infection","enrollment":48},{"nctId":"NCT02482077","phase":"PHASE4","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":112},{"nctId":"NCT02932293","phase":"PHASE2","title":"Triple Combination DAAs for Treating HCV GT1b Subjects","status":"WITHDRAWN","sponsor":"Humanity and Health Research Centre","startDate":"2016-12","conditions":"Chronic Hepatitis C Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["sofosbuvir","daclatasvir"],"phase":"phase_3","status":"active","brandName":"Combined Therapy SOF and DCV","genericName":"Combined Therapy SOF and DCV","companyName":"Yassin Abdelghaffar Charity Center for Liver Disease and Research","companyId":"yassin-abdelghaffar-charity-center-for-liver-disease-and-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes. Used for Chronic hepatitis C virus infection (genotype-dependent).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}